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ABSTRACT
Cancer cells are thought to use actin rich invadopodia to facilitate matrix 
degradation. Formation and maturation of invadopodia requires the co-ordained 
activity of Rho-GTPases, however the molecular mechanisms that underlie the 
invadopodia lifecycle are not fully elucidated. Previous work has suggested a 
formation and disassembly role for Rho family effector p-21 activated kinase 1 (PAK1) 
however, related family member PAK4 has not been explored. Systematic analysis of 
isoform specific depletion using in vitro and in vivo invasion assays revealed there 
are differential invadopodia-associated functions. We consolidated a role for PAK1 in 
the invadopodia formation phase and identified PAK4 as a novel invadopodia protein 
that is required for successful maturation. Furthermore, we find that PAK4 (but not 
PAK1) mediates invadopodia maturation likely via inhibition of PDZ-RhoGEF. Our work 
points to an essential role for both PAKs during melanoma invasion but provides a 
significant advance in our understanding of differential PAK function.
INTRODUCTION
Whilst the survival rate for patients suffering from 
early stage melanoma is good, a significant proportion 
of patients will go on to develop metastatic disease [1]. 
Metastasis requires the coordinated rearrangement of the 
actin cytoskeleton as the melanoma cells move through 
tissue, a process thought to be regulated by Rho Family 
GTPases and their downstream effectors [2]. Moreover, 
during stromal invasion cancer cells are believed to form 
protease secreting invasive protrusions rich in actin [3, 4] 
termed invadopodia. Invadopodia are now reported both in 
vitro and in vivo and recent evidence suggests the invasive 
protrusion plays an active role in promoting metastasis [5–7].
The p-21 activated kinase (PAK) family of serine/
threonine kinases are known effectors of Rho GTPases 
that control cytoskeletal dynamics and cell movement [2]. 
Human PAKs consist of 6 isoforms, which are separated 
into two groups according to their sequence and structural 
homology: group I, containing PAKs 1-3; and group II, 
containing PAKs 4-6. The overexpression of PAKs is 
found in a wide variety of human cancers and is often 
associated with an increase in invasive potential [2]. 
Indeed, PAK1 has been shown to localise to invadopodia 
protrusions [8], however, studies investigating the specific 
function of this protein in invadopodia formation/function 
have yielded conflicting results. To date, no studies have 
suggested a role for PAK4 in the invadopodia lifecycle. 
Moreover, the protein expression level and functional 
properties of the PAKs in melanoma invasion has not been 
explored.
PAK1 and PAK4 exhibit less than 55% sequence 
homology suggesting that these family members could 
drive divergent functions [9]. However, whilst multiple 
common substrates have been identified (e.g LIMK [10, 
11], paxillin [12, 13] ) there are virtually no confirmed 
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isoform specific substrates reported [2] and directly 
comparable functional studies of PAK1 and PAK4 are rare. 
There is a particular level of complexity surrounding the 
role of PAK1/PAK4 in regulation of RhoA activity. PAK4 
is purported to contain a GEF interacting domain (GID) 
[14] not found in PAK1, however both PAK1 and PAK4 
have been reported to inhibit RhoA activator, GEF-H1 
[14–16]. Nevertheless, whilst it has been previously 
reported that PAK4 depletion can elevate the level of 
RhoA activity [17], in contrast RhoA activation has not 
been observed in PAK1 depleted cells [18]. Interestingly, 
PAK1 and PAK4 may exhibit differential binding to a 
second RhoA activator, PDZ-RhoGEF [19, 20] a protein 
recently associated with invadopodia [21]. However, to 
date the PAK4:PDZ-RhoGEF interaction has not been 
associated with cellular activity. Despite the difficulties 
in separating PAK1 and PAK4 function mouse knockout 
(KO) phenotypes suggest that at least for PAK4 there 
are isoform specific functions as PAK4 KO mice are 
embryonically lethal whilst PAK1 KO mice remain viable 
and fertile [22, 23].
In this study we demonstrate that PAK1 and PAK4 
expression at the protein level is significantly increased 
in melanoma compared to melanocyte controls using 
both cell lines and patient derived cell strains. Moreover 
we find a correlation between invasive potential and 
PAK expression. Our subsequent systematic analysis of 
isoform specific depletion in invasive cells has revealed 
that PAK1 and PAK4 are both required for in vitro and 
in vivo invasion. In addition our approach has allowed us 
to detect isoform specific functions during the invadopodia 
life cycle whereby PAK1 functions early in formation 
whilst PAK4 drives maturation. We have been able to 
demonstrate that PAK4, and not PAK1, regulates the 
activity levels of RhoA in invasive cells. Furthermore we 
find that during invadopodia maturation PAK4 is required 
to suppress RhoA activity in the invadopodia via inhibition 
of PDZ-RhoGEF. Taken together our work points to 
essential requirements for both PAK1 and PAK4 during 
melanoma invasion and further provides clear evidence of 
differential function.
RESULTS
PAK1 and PAK4 expression correlates with 
invasive potential
We sought to initially define the invasive potential 
of a panel of melanoma cell lines and subsequently 
correlate invasive potential with PAK expression levels. 
We have adopted the invadopodia assay [24–26] and 
3D spheroid assay [27–29] as our measures of invasive 
potential. Melanocytes do not produce invadopodia 
and not all melanoma derived cells lines are able to 
produce invadopodia (Figure 1A–1C); validated by 
the co-localisation of cortactin with F-actin staining 
and gelatin degradation (Supplementary Figure S1A) 
which defines completion of the invadopodia lifecycle. 
Interestingly, both PAK1 and PAK4 were overexpressed 
in those cell lines which were able to form invadopodia 
(Figure 1D–1E). Importantly, ability to form invadopodia 
was semi-predictive of 3D invasion potential (Figure 
1F–1H) when cell proliferation rates were normalised 
(Supplementary Figure S1B). Where the two cell lines 
with the highest level of invadopodia activity (Figure 1B) 
also achieved the highest level of cell invasion (Figure 
1H). Of the other PAK isoforms, only PAK2 was found 
to be overexpressed in melanoma cell lines, compared 
to melanocytes (Supplementary Figure S1C). This is not 
surprising given that PAK2 expression is already known 
to be overexpressed in melanoma cells [30] and important 
in invasion [31]. Recent publications have suggested 
that the formation of invadopodia is not restricted to 
cell culture conditions [5, 6], however, human cells 
directly derived from melanoma patients have not been 
tested. Interestingly, we found that not all patient cell 
strains were able to exhibit invadopodia activity (Figure 
2A–2C) and invadopodia formation was not always 
correlated with pathological classification at time of 
biopsy in terms of origin; primary versus metastatic lesion 
(Table 1). However, we consistently detected high levels 
of PAK1 and PAK4 expression in the invasive cell strains, 
particularly M35 (Figure 2D–2F). Moreover, PAK1 and 
PAK4 were expressed in all the patient samples tested.
PAK1 and PAK4 are required for melanoma cell 
invasion in vitro and in vivo
Our results suggest that both PAK1 and PAK4 
could play a role during melanoma invasion. To further 
investigate specific PAK1 and PAK4 functionally the 
two proteins were depleted in two invasive melanoma 
cell lines (WM-115 and A-375M2) (Figure 3A–3B). 
We were able to sustain siRNA induced PAK1 and 
PAK4 depletion for seven days (Supplementary Figure 
S1D-S1E). Reduced expression of PAK1 and PAK4 in 
both WM-115 and A-375M2 cells decreased invasion 
(Figure 3C) and double depletion of PAK1 and PAK4 
expression resulted in a further reduction in invasive 
potential (Figure 3C–3E). Depletion of PAK1 and PAK4 
also decreased the percentage of cells that produced 
degradative invadopodia in both WM-115 and A-375M2 
cells (Figure 3F–3H). Moreover, treatment of cells with 
the PAK1 specific inhibitor IPA-3 significantly reduced 
the level of invadopodia formation (Supplementary Figure 
S1F) confirming the dependence on PAK1 kinase activity 
previously reported [26]. Having established a requirement 
for PAK expression in vitro we then sought to translate 
our findings in vivo. We generated stable shRNAi bi-
cistronic GFP control, PAK1 or PAK4 depleted A-375M2 
cell lines [17] (Figure 4A) and performed the in vivo the 
zebrafish yolk invasion assay [32–34] (Figure 4B). Cells 
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Figure 1: Invasive melanoma cell lines overexpress PAK. A. Representative invadopodia assay images. Cells were seeded on 
rhodamine conjugated gelatin for 3 hrs and stained for F-actin. Actin rich dots corresponding with gelatin degraded dots were counted 
as invadopodia. The degradation was measured using ImageJ software. Scale bars = 20µm. B. The percentage of cells with invadopodia. 
Significance was calculated to a melanocyte control. 150 cells, over 3 independent experiments; * = P 00< 0.05. C. The area of degradation 
from invadopodia per cell. Significance was calculated between all cell lines. 90 invadopodia producing cells, over 3 independent 
experiments; * = P 00< 0.05. D-E. Western blot of PAK1 (D) and PAK4 (E) expression in melanoma cell lines compared to melanocytes. 
over 3 independent experiments; *= P 00< 0.05. Densitometric data were normalized to a GAPDH loading control. F. Spheroid assay. 
Examples of invading cells are indicated by black arrows. Scale bar = 100µm. G. Quantification of the number of cells that had invaded 
surrounding matrix H. the number of cells that invaded further than 100µm from the spheroid mass. Cells were seeded as determined 
by a proliferation assay (Supplementary Figure S1B). Significance was calculated to melanocytes. of 9 spheroids over 3 independent 
experiments; * = P 00< 0.05. In all cases data are mean values ± S.E.M.
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Figure 2: Invasive Patient Derived Cell Strains Overexpress PAK1 and PAK4. A. Representative images of the patient 
derived cell strain invadopodia assay. Patient derived cell strains were derived from primary (M133, M586 and M460) or metastatic tissue 
(M581, M575 and M35). Magnification box present in bottom left corner of M586 images, indicated by white borders. Cells were seeded 
on rhodamine conjugated gelatin for 24hrs and stained for F-actin. Invadopodia were scored as described in Figure 1. The degradation 
was measured using ImageJ software. Scale bars = 20µm. B. The percentage of cells with invadopodia. Significance was calculated to 
melanocytes. of 150 cells, over 3 independent experiments; * = P 00< 0.05. C. The area of degradation per cell. Significance was calculated 
between all cell lines. 90 invadopodia producing cells, over 3 independent experiments; * = P 00< 0.05. D-F. Western blot of PAK1 and 
PAK4 protein expression in patient derived cell strains and melanocytes. Significance was calculated to melanocytes (1). 3 independent 
experiments; *= P 00< 0.05. Densitometric data were normalized to a GAPDH loading control. In all cases data are mean values ± S.E.M.
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were injected into the yolk sac of zebrafish embryos at 
2 days post fertilisation (dpf). Control cells were able to 
invade through the yolk and intravasate into the embryo 
vasculature where they lodged in the tail (Figure 4B–4E). 
However, tail invasion events were significantly reduced 
using cells with stably depleted PAK1 or PAK4 expression 
(Figure 4C–4E). Therefore, using three different 
experimental assays we have demonstrated that reducing 
PAK1 or PAK4 expression can inhibit the invasion of 
melanoma cells.
PAK1 and PAK4 have differential functions in 
the invadopodia lifecycle
Whilst our work has outlined important roles in 
melanoma invasion we have not identified any differential 
function. Initially, we validated a specific requirement 
for PAK1 and PAK4 isoforms by re-expressing siRNA 
resistant GFPPAK1r and GFPPAK4r (Figure 5A–5B) in a 
depleted background. Under these conditions invadopodia 
formation and degradation were restored back to control 
levels (Figure 5C–5E). We then proceeded to test PAK 
isoform redundancy. Expression of PAK1GFP in PAK4 
depleted cells was unable to recover the percentage of 
cells with invadopodia, nor the level of matrix degradation 
(Figure 5F–5H), thus increased levels of PAK1 are unable 
to compensate for loss of PAK4. Exogenous expression 
of PAK4GFP, in contrast, whilst unable to elevate the 
percentage of cells with invadopodia, did induce an 
increase in maturation in those invadopodia present in a 
PAK1 depleted population (Figure 5I-5K). This suggests 
that PAK1 and PAK4 have unique functions in invadopodia 
dynamics and that PAK4 may act downstream of PAK1. 
Having identified a potential differential function we more 
carefully examined the presence of actin puncta as an 
indicator of invadopodia initiation. We noted that whilst 
depletion of PAK1 expression reduced the percentage of 
cells with actin puncta (initiation of invadopodia formation 
[35]), reduction of PAK4 expression had no effect on the 
percentage of cells with actin puncta (Figure 6A–6B).
PAK4 depleted cells fail to efficiently complete 
the invadopodia lifecycle
Our data (Figure 5 & 6) suggest that although 
the outcome of both PAK1 and PAK4 expression is a 
loss of degradation, PAK1 is required in the formation 
stage, whilst PAK4 activity is required during the later 
maturation stage. To further explore the failure of 
PAK4KD cells to complete the lifecycle we monitored 
the localisation of MT1-MMP to the actin puncta. We 
observed a significant reduction in MT1-MMP localisation 
to nascent invadopodia in our PAK4 depleted cells (Figure 
6C). Thus these data further support differences in the 
functional role of PAK1 and PAK4 during the invadopodia 
lifecycle.
PAK4 signals via PDZ-RhoGEF to promote 
invadopodia function
Having identified specific roles for PAK1 and PAK4 
during the invadopodia lifecycle we proceeded to focus 
on identifying an underlying molecular mechanism. PAK1 
has already been reported to drive invadopodia formation 
via phosphorylation of cortactin and thus we focussed on 
PAK4, which had not previously been associated with 
invadopodia activity. We noted that PAK4 but not PAK1 
depleted cells exhibited a significantly increased level of 
actin stress fibres (Figure 6D). An increase in prominent 
actin fibres has been linked to cell rigidity and reduced 
cell invasion [36]. Indeed, an increase in prominent 
actin fibres was reported in PAK4 depleted DU-145 
cells [17]. Here, PAK4 depletion induced stress fibre 
formation was attributed to an increased level of GTP-
loaded RhoA [17]. We have used a RhoA biosensor [37] 
to quantitatively measure the level of RhoA activation in 
individual cells. Increased RhoA activity was detected in 
cells when PAK4 levels were reduced, compared to the 
control cells (Figure 6E–6F). Conversely, when PAK1 
levels were diminished there was a decrease in detectable 
RhoA activity, compared to the control (Figure 6E–6F). 
Table 1: Clinical data for patient derived cell strains
Cell Strain Origin Patient Stage at 
Time of Biopsy
Age at Time of 
Biopsy
Disease 
Progression
BRAF Mutation 
(V600E)
M35 Metastasis IIIC 57 YES Mutated
M460 Primary IIIA 44 YES Wildtype
M575 Metastasis IIIB 92 YES Unknown
M586 Primary IIC 92 NO Unknown
M581 Metastasis IIIB 71 NO Wildtype
M133 Primary IIC 75 NO Unknown
Patient staging according to the AJCC staging system [71]. Disease progression indicated an increase in staging or patient 
death from melanoma between the date of the biopsy excision and August 2014
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Figure 3: Depletion of PAK protein expression reduces invadopodia formation. A-B. Transient depletion of PAK1 (A) and 
PAK4 (B) expression in the WM-115 and A-375M2 cell lines at 4 days post siRNA transfection. A double knockdown was performed using 
PAK1 Oligo 1 and PAK4 Oligo 2 oligonucleotides. Control cells were transfected with a control non targeting siRNA. Significance was 
calculated for protein depleted cell lines compared to wildtype. over 3 independent experiments; *= P 00< 0.05. Densitometric data were 
normalized to GAPDH, which was used as a loading control. C. Representative images of the 3D spheroid invasion assay Examples of 
invading cells are indicated by black arrows. Scale bar = 100µm. D. Quantification of the number of cells that had invaded surrounding 
matrix E. the number of cells that invaded further than 100µm from the spheroid mass. Significance was calculated to wildtype. 9 spheroids 
over 3 independent experiments; * = P 00< 0.05. F. Representative invadopodia assay images of WM-115 cells in which PAK1 and 
PAK4 proteins are depleted. The degradation was measured using ImageJ software. Scale bars = 10µm. The percentage of cells with 
invadopodia G. and the area of degradation from invadopodia per cell H.. Significance was calculated to wildtype cells. 150 (Percentage) 
or 90 (Degradation) cells, over 3 independent experiments; * = P 00< 0.05. In all cases data are the mean values ± S.E.M.
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Thus, the level of RhoA activation differs in PAK1 and 
PAK4 knockdown cells. We have shown that specific loss 
of PAK4 expression concomitantly reduces the invasive 
potential of melanoma cells and increases the level of 
RhoA activity. Whilst previous work has indicated that 
reduced RhoA expression inhibits invadopodia formation 
[38] there are also reports that a constitutively active 
RhoA mutant reduced the podosome induced degradation 
by v-Src transformed NIH3T3 cells [39]. Together these 
findings suggest that a balance of RhoA activity and 
inactivation may be important for function. Therefore, we 
hypothesised that PAK4 may be required to reduce levels 
of RhoA activation during the invadopodia maturation 
stage. PAK4 has previously been shown to inhibit the 
activation of RhoA via the phosphorylation and inhibition 
of Rho guanine nucleotide exchange factors (GEFs) 
Figure 4: Depletion of PAK reduces melanoma invasion in vivo. A. Stable reduction of PAK1 and PAK4 in the A-375M2 cell 
line. B. Diagrammatic representation of the invasive cell movement during the yolk invasion assay, including: (i) Tumour intravasation into 
blood vessels; (ii) Transportation in the blood vessels; and (iii) cells lodge in tail vessels and extravasate. C. Phase contrast and fluorescent 
images of zebrafish embryos at 4 dpi for embryos injected with control, PAK1 and PAK4 depleted cells (C). Red stars indicate cell mass in 
yolk sac (original injection site). White arrows indicate tail invasion of GFP labelled cells. Scale bar = 500µm. D. High magnification of tail 
invasion E. The percentage of embryos with cell tail invasion. Significance was calculated compared to control shRNA cells. Data are the 
mean values ± S.E.M., over at least 3 independent experiments; n = total number of embryos, *= P 00< 0.05.
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Figure 5: Isoform specific PAK1 and PAK4 functions during the invadopodia lifecycle. A-B. Confirmation of siRNA resistant 
protein expression in PAK1 (A) or PAK4 (B) siRNA depleted WM-115 cells. C. Representative invadopodia assay images of WM-115 
depleted cells transfected with GFPPAK1r or GFPPAK4r. Scale bars = 10µm. D. The percentage of cells with invadopodia and E. the area 
of degradation from invadopodia. Significance was calculated to control siRNA transfected cells.. of 150 (Percentage) or 90 (Degradation) 
cells, over 3 independent experiments; * = P 00< 0.05. F. Representative invadopodia assay images of WM-115 PAK4 knockdown cells 
transfected with GFP alone or GFPPAK1. Scale bars = 10µm. G. The percentage of cells with invadopodia. Significance was calculated to 
control siRNA transfected cells. 150 cells, over 3 independent experiments; * = P 00< 0.05. H. The area of degradation from invadopodia per 
cell. Significance was calculated to control siRNA transfected cells. 90 invadopodia producing cells, over 3 independent experiments; * = P 
00< 0.05. Control = cells transfected with non-specific siRNA. I. Representative invadopodia assay images of WM-115 PAK1 knockdown 
cells transfected with GFP alone or GFPPAK4. Scale bars = 10µm. J. The percentage of cells with invadopodia. Significance was calculated 
to control siRNA transfected cells. 150 cells, over 3 independent experiments; * = P 00< 0.05. K. The area of degradation from invadopodia 
per cell. Significance was calculated to control siRNA transfected cells. 90 invadopodia producing cells, over 3 independent experiments; 
* = P 00< 0.05. Control = cells transfected with non-specific siRNA. In all cases data are mean values ± S.E.M
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Figure 6: Differential PAK1 and PAK4 signalling in invasive cells. A. Representative F-actin images of WM-115 and A-375M2 
cells with deleted PAK1 and PAK4 expression (individually and simultaneously). Scale bar = 10µm. B. The percentage of cells with 
actin puncta on gelatin. Significance was calculated to wildtype cells. 150 cells, over 3 independent experiments; * = P 00< 0.05. C. Co-
localisation of mCherry-MT1-MMP with F-actin on gelatin. Scale bar = 20µm. The percentage of cells with actin puncta localisation with 
MT1-MMP. Significance was calculated to wildtype cells. 30 cells, over 3 independent experiments; * = P 00< 0.05. D. Percentage of WM-
115 and A-375M2 cells with prominent actin fibres on gelatin. Significance was calculated to wildtype cells. 150 cells, over 3 independent 
experiments; * = P 00< 0.05. E-F. FRET analysis of RhoA activation in A-375M2 RhoA cells in which PAK1 and PAK4 expression was 
diminished. Significance was calculated to control cells over 3 independent experiments; * = P 00< 0.05. In all cases data are mean values 
± S.E.M.
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such as GEF-H1 [14, 17]. However, initial experiments 
found no modulation of GEF-H1 phosphorylation in 
cells with PAK1/PAK4 depletion (Supplementary Figure 
S2A-S2B). Indeed, interaction with GEF-H1 would not 
differentiate between PAK1 and PAK4 [16, 17, 40]. In 
contrast, previous reports have suggested that PAK4 (but 
not PAK1) can bind to, and inhibit the GEF activity of, 
PDZ-RhoGEF [19, 20]. Moreover, PDZ-RhoGEF has 
recently been reported to function in invadopodia27. We 
found PDZ-RhoGEF is expressed in both of our invasive 
melanoma cells (Supplementary Figure S2C) and we have 
now confirmed the preferential binding of PAK4 to PDZ-
RhoGEF (Figure 7A). Thus PAK4 regulation of RhoA 
activity during the invadopodia life cycle could occur via 
PDZ-RhoGEF. To investigate our hypothesis, a dominant 
negative PDZ-RhoGEF mutant (myc-PDZ-RhoGEFΔDH 
[41]) was expressed in cells. This mutant is reported to 
inhibit RhoA activity [41, 42] and should therefore be able 
to rescue the PAK4 depletion phenotype. Expression of 
myc-PDZ-RhoGEFΔDH was able to rescue the percentage 
of cells with degradative invadopodia in PAK4 depleted 
cells to control levels (Figure 7B–7D) concomitant with a 
reduction in prominent actin fibres (Figure 7E). Moreover, 
importantly myc-PDZ-RhoGEFΔDH expression was 
unable to rescue the percentage of cells with invadopodia 
or the level of gelatin degradation in PAK1 depleted 
cells (Supplementary Figure S2D-2F). This further 
supports a specific PAK4:PDZ-RhoGEF interaction to 
inhibit RhoA activity during invadopodia maturation. 
Thus we predicted that an increase in RhoA activity 
by overexpression of PDZ-RhoGEF should negatively 
interfere with invadopodia maturation. In line with this 
hypothesis we find that exogenous expression of myc-
PDZ-RhoGEF in WM-115 cells reduced invadopodia 
maturation compared to wildtype cells, mimicking the 
PAK4 knockdown phenotype (Figure 7F–7H). Moreover, 
PDZ-RhoGEF expression increased the percentage of 
cells with prominent actin fibres compared to wildtype 
cells (Figure 7I). Thus we predict a novel role for both 
PAK4 and PDZ-RhoGEF where PAK4 drives invadopodia 
maturation via inhibition of PDZ-RhoGEF induced RhoA 
activity, indeed a kinase dead variant of PAK4 cannot 
rescue the loss of invadopodia phenotype (Supplementary 
Figure S3). Interestingly, we are able to localise both 
GFPPAK4 and myc-PDZ-RhoGEF to invadopodia 
structures (Figure 7J), suggesting that PDZ-RhoGEF 
activity is required earlier in the invadopodia lifecycle but 
that inhibition by PAK4 is essential to achieve maturation.
DISCUSSION
PAK1 and PAK4 protein levels were elevated in 
invasive melanoma cell lines and cells derived from 
patient samples. This study used the invadopodia assay 
as an indicator of invasive potential, alongside a 3D 
and an in vivo invasion assay, to investigate the role of 
PAK1 and PAK4 in melanoma invasion. Whilst PAK1 
activity was clearly associated with nascent invadopodia 
formation PAK4 depletion revealed a differential role 
during invadopodia maturation. Thus by systematic 
analysis of PAK isoform deletion we have been able to 
assign differential function. Moreover, subsequent studies 
were able to specifically assign a PAK4:PDZ-RhoGEF 
interaction to the invadopodia maturation stage. These 
data therefore reveal novel functions for both PAK4 and 
PDZ-RhoGEF and provide clear evidence of differential 
function between these two widely studied by rarely 
compared PAK family members.
In both melanoma cell lines and patient derived cell 
strains a positive correlation was observed between the 
level of PAK1 protein expression and cell invasiveness. 
These findings complement previous studies linking PAK1 
with increased invasiveness of uveal melanoma [43]. 
This suggests a global melanoma requirement for PAK1. 
Furthermore, PAK1 was found to be overexpressed in 
mouse malignant squamous cell carcinoma (SCC) [44]. 
Previous research suggested that PAK1 overexpression is 
restricted to a wildtype BRAF subset [45]. Though possibly 
the case for primary melanoma, our study has shown that 
this is not the case when investigating metastatic melanoma, 
where PAK1 overexpression correlates with invasion (rather 
than BRAF mutational status).
PAK4 was robustly overexpressed in the melanoma 
cell lines, including the invasive cells. However, high levels 
of PAK4 alone did not specifically correlate with invasive 
ability. Rather we would suggest that cells need high levels 
of both PAK1 and PAK4 to achieve efficient invasion. 
A hypothesis which fits with PAK1 being upstream of 
PAK4 in the invadopodia lifecycle. An increase in PAK4 
mRNA in melanoma cell lines, compared to melanocytes, 
suggests that the upregulation may also be occurring at 
the transcriptional level [46]. PAK isoforms (of which 
there are 6) are overexpressed in a wide variety of human 
tumours such as breast, colon, prostate and ovarian cancer 
[47]. PAK1 has been previously found to promote the 
cell invasion of colon cancer [48] and breast cancer cell 
lines [18]. Similarly, PAK4 promotes the cell invasion 
of choriocarcinoma [49] and endometrial cancer [50]. 
Moreover, in skin cancer specifically, PAK1 and PAK4 
promote cell invasion of uveal melanoma [43] and SCC 
[44] cell lines, respectively. However, the role of these 
proteins in skin melanoma invasion is undefined. We found 
that depleting either PAK1 or PAK4 significantly reduced 
invadopodia maturation and subsequent matrix degradation 
in melanoma cells and found that PAK1 or PAK4 expression 
are required for efficient invasion in 3D and in vivo invasion 
assays. The data presented here complements previously 
published studies with other cancer types and suggests a 
global involvement for PAK1 and PAK4 in cancer invasion 
at least in vitro [18, 43, 44, 48–50].
Previous studies have specifically shown that PAK1 
localises to invadopodia [8] and that the inhibition of 
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Figure 7: PAK4 mediates invadopodia dynamics via PDZ-RhoGEF. A. Immunoprecipitation in HEK293 cells of GFP-PAK1/
PAK4 in the presence/absence of myc-PDZ-RhoGEF expression with a myc-PDZ-RhoGEF alone control. The Immunoprecipitation 
was probed for presence of myc-PDZ-RhoGEF B. Representative images of PAK4 knockdown WM-115 cells expressing myc-PDZ-
RhoGEFΔDH. Scale bars = 10µm. The percentage of cells with invadopodia C. the area of degradation D. and the percentage of cells with 
prominent actin fibres E. in PAK4 knockdown cells expressing myc-PDZ-RhoGEFΔDH. Significance was calculated to control WM-115 
cells. Data are mean values ± S.E.M. of 150 (Percentage of invadopodia and prominent actin fibres) or 90 (Degradation) cells, over 3 
independent experiments; * = P 00< 0.05. F. Representative images of WM-115 cells expressing myc-PDZ-RhoGEF. Scale bars = 10µm. 
The percentage of cells with invadopodia G. the area of degradation H. and the percentage of cells with prominent actin fibres I. in cells 
expressing myc-PDZ-RhoGEF. Significance was calculated to wildtype WM-115 cells. J. Co-localisation of GFPPAK4 and myc-PDZ-
RhoGEF (wildtype and ΔDH mutant) with F-actin and TRITC gelatin degradation. Scale bar = 10µm.
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endogenous PAK1 via an autoinhibitory domain fragment, 
can reduce the formation of invadopodia in A375MM cells 
[26]. Our findings complement this work, providing further 
evidence that PAK1 is important in invadopodia formation 
in melanoma. In contrast, PAK1 has been associated with 
Rac mediated invadopodia dissolution in a breast cancer 
cell line, thus PAK1 function in invadopodia may be cell 
type specific [8]. PAK4 localises to and promotes the 
formation of podosomes, a structure that often shares 
similar proteins to invadopodia [51, 52]. However, the 
work presented here is the first to demonstrate that PAK4 
is localised to invadopodia and involved in invadopodia 
maturation.
PAK1 and PAK4 are activated differently [2], 
however little is known about the unique signalling 
pathways or the substrates of these two family members 
and how these differences may impact on the effect 
that these proteins have on the invasive potential of 
tumours [23]. A better understanding of isoform specific 
differences in downstream signalling could help guide 
the further development of therapeutic agents. Currently, 
pharmaceutical companies are focused on developing 
group or isoform specific inhibitors [53–55]. Therefore, 
data indicating whether both groups contribute to invasion 
and metastasis in the same way, may determine whether 
the use of cross reactive inhibitors is more beneficial than 
isoform specific inhibitors in treating some cancers types. 
However, consideration of increased risk of side effects 
from a pan-PAK inhibitor would be critical.
Depletion of PAK1 reduced both the percentage of 
cells with invadopodia and also the matrix degradation 
for those cells that formed invadopodia. In addition, 
reduction of PAK1 protein expression also reduced the 
number of nascent invadopodia actin puncta, suggesting 
an important role for this protein early in the formation 
stage of the invadopodia lifecycle. Furthermore, PAK1 
kinase activity was required for efficient invadopodia 
formation supporting a role for substrate phosphorylation 
in line with previous reports [26]. In contrast, PAK4 
protein depletion did not reduce the formation of nascent 
actin puncta but did inhibit maturation. These findings are 
in agreement with previous studies that suggested PAK4 
is required for podosome function [51, 52]. It is possible 
that PAK4 is responsible for promoting the expression 
of proteases involved in matrix degradation, as has been 
previously reported in other cell types, such as MMP-
2 [50, 56, 57], MMP-9 and MT1-MMP [49]. However, 
we specifically localised PAK4 to mature invadopodia 
suggesting a structural/functional role at the protein level. 
Furthermore, we confirmed that PAK4, but not PAK1, 
can bind to PDZ-RhoGEF which was also localised to 
invadopodia. PDZ-RhoGEF is known to preferentially 
activate RhoA, over RhoB and RhoC [58], and previous 
work has demonstrated that PAK4 can negatively regulate 
PDZ-RhoGEF [19]. We now find that PAK4 depleted 
melanoma cells exhibit elevated levels of RhoA activity. 
Furthermore, PDZ-RhoGEF dominant negative mutants, 
while able to rescue invadopodia function in PAK4 
depleted cells, have no effect on invadopodia formation 
in PAK1 depleted cells. The localisation of PDZ-RhoGEF 
within invadopdia27 suggests that there is a stage in the 
invadopodia life cycle when PDZ-RhoGEF mediated 
RhoA activity is required. Indeed, studies suggest that 
RhoA activity is essential during invadopodia formation 
[38] and to regulate MT1-MMP delivery [59]. However, 
work with podosomes suggests that a balance of RhoA 
activation and inactivation is important for podosome 
function [39, 60–62]. We detected a variation in the 
level of PDZ-RhoGEF expression between our invasive 
melanoma cell lines, however we would suggest that 
global expression levels are not necessarily an indicator 
of activity. Rather the importance is regulated spacial and 
temporal localisation within invadopodia. We hypothesise 
that RhoA inactivation is required to promote maturation; 
an inactivation delivered by the interaction between 
PAK4 and PDZ-RhoGEF. Indeed, expression of kinase 
dead PAK4 was unable to rescue the PAK4 depletion 
phenotype emphasising the need for kinase activity. We 
would speculate based on our MT1-MMP studies that this 
interaction is required for the final delivery of proteases 
involved in matrix degradation to the invadopodia 
core and/or retention of MMPs within the invadopodia 
structure; given that PAK4 and PDZ-RhoGEF are localised 
there. This hypothesis is supported by our observation that 
a dominant negative PDZ-RhoGEF can revert the loss of 
mature degradative invadopodia in PAK4 depleted cells. 
Our data clearly points to a specific role for PDZ-RhoGEF 
in regulating invadopodia dynamics however we cannot at 
this stage conclusively rule out the involvement of other 
RhoA regulators downstream of PAK4. Indeed, further 
examination of the relationship between PAK4 and PDZ-
RhoGEF within the invadosome is warranted.
Little is known about the role that PDZ-RhoGEF 
plays in tumour invasion, although a potential role in 
invadopodia dynamics was recently reported [21]. Gene 
amplification of PDZ-RhoGEF is evident in gallbladder 
cancer specimens, compared to normal tissue [63] thus 
it will be of interest to observe if PDZ-RhoGEF levels 
are prognostic of invasive potential. Our hypothesis 
proposes that a reduction in RhoA activity is required to 
complete the invadopodia life cycle. This is consistent 
with a the recent finding that invadopodia activity requires 
suppression of Rho signalling [64] and previous work 
that suggests that efficient invasion requires localised 
suppression of Rho signalling [65–68]. Whilst our work 
highlights the importance of MT1-MMP delivery it 
could also be the case that a reduction in RhoA activity is 
required to reduce contractility and allow extension of the 
forming the protrusion [69] which would in turn promote 
MT1-MMP activity. It will be interesting to explore further 
the specific functional consequences of Rho suppression 
during the invadopodia lifecycle.
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This study clearly demonstrates that PAK1 and 
PAK4 play an important role in melanoma cell invasion. In 
addition, we have been able to identify isoforms specific 
functions during the invadopodia life cycle; where PAK1 
drives formation and PAK4 promotes maturation through 
the localised inhibition of PDZ-RhoGEF. Importantly, 
our data supports the development of pan-PAK inhibitors 
which block the function of both the group I and group 
II PAKs as a viable treatment option for metastatic 
melanoma.
MATERIALS AND METHODS
Antibodies and reagents
Anti-PAK1, anti-PAK2 and anti-GEFH-1 were 
purchased from Cell Signalling Technology. Anti-c-Myc 
and anti-PAK5 were acquired from Santa Cruz. Anti-
Cortactin from Upstate. Anti-GAPDH from Millipore. 
Anti-p-GEFH-1 (Ser885) from Abcam. Anti-PAK3 from 
New England Biolabs and anti-PAK6 from Calbiochem. 
Anti-GFP from Roche Life Science. Anti-β-Actin and 
anti-β-Tubulin from Sigma Aldrich. Anti-HMWMAA 
and anti-human IgG kind gift from Sophia Karagiannis, 
King’s College London (KCL). Anti-PAK4 was previously 
described [17]. Horseradish peroxidase (HRP) conjugated 
secondary antibodies were purchased from DAKO. The 
Alexa Fluor 488 conjugated antibodies and Phalloidin 
from Invitrogen. GFP-PAK1r, GFP-PAK4r, HA-PAK4r 
and HA-PAK4K350/351Mr were constructed by site-
directed mutagenesis, according to the manufacturer’s 
instructions, using the QuikChange Multisuite II kit 
(Stratagene). The Myc-PDZ-RhoGEF and Myc-PDZ-
RhoGEFΔDH were kind gifts from John Masters, 
University College London (UCL). The RhoA Biosensor 
was generously provided by Maddy Parsons, (KCL). IPA-
3 was purchased from Sigma.
Cell culture
HEK 293 cells were grown in Dulbecco’s modified 
eagle’s medium (DMEM), the melanoma cell lines 
A-375M2, SK-MEL-2 and SK-MEL-28 were grown in 
Dulbecco’s modified eagle’s medium: nutrient F-12 ham 
(DMEM F-12) (containing L-glutamine), and the WM-
115 cell line was grown in minimum essential medium 
(MEM) (containing L-glutamine). All the growth media 
supplemented with 10% foetal bovine serum (FBS), 
penicillin and streptomycin sulphate. Human melanocytes 
were cultured in epidermal melanocyte basal growth 
medium to which was added epidermal melanocyte 
growth supplement and antibiotic supplement, according 
to the manufacturer’s instructions (TCS Cellworks). WM-
115 cells were transiently transfected with X-tremeGENE 
HP transfection reagent and the A-375M2 cells using 
Lipofectamine® 2000 transfection reagent, according to 
the manufacturer’s instructions. The human melanoma 
tumour tissues were obtained with written informed 
consent and all work was approved by the Guy’s 
Research Ethics Committee, Guy’s and St. Thomas’ NHS 
Trust (reference number 08/H0804/139, approval date 
15/10/2008). Isolation of melanoma cells was performed 
using fluorescence activated cell sorting (FACS) by flow 
cytometry. For inhibitor studies cells were incubated with 
DMSO or 5uM IPA-3 for 2 hours prior to the invadopodia 
assay.
Si/Sh RNA
Oligonucleotides (Dharmacon, UK) were 
transiently transfected at a concentration of 25nM using 
HiPerFect transfection reagent (Qiagen), according 
to the manufacturer’s instructions. ShRNAi vectors 
(pGIPz ;Open Biosystems), were transfected into cells 
using Lipofectamine® transfection reagent (Invitrogen). 
Knockdown cells were selected and maintained in media 
containing 1µg/ml puromycin.
Western blotting
Proteins were separated by electrophoresis and 
transferred onto protran nitrocellulose hybridization 
transfer membranes. The membranes were blocked and 
subsequently incubated overnight at 4°C in primary 
antibody in TBST with 1% (w/v) non-fat milk powder or 
BSA. The membranes were washed three times in TBST 
and then incubated for 1 hr at room temperature with the 
respective HRP secondary in TBST with 1% (w/v) non-
fat milk powder or BSA. Proteins were detected using 
Pierce® enhance chemiluminescence (ECL) western 
blotting substrate and analysed using ImageJ software.
Immunofluorescence staining
Cells were fixed with 4% (w/v) paraformaldehyde 
(PFA) and permeabilised using 0.2% (v/v) triton X-100 
and then washed with PBS. For FRET experiments, the 
autofluorescence was quenched in sodium borohydride. 
Non-specific binding was blocked by 3% BSA. Coverslips 
were incubated for 2 hours with the primary antibody and 
then washed with PBS. Cells were incubated for 1 hour 
with secondary antibody and fluorophore conjugated 
phalloidin. Coverslips were then washed with PBS and 
mounted using Fluorsave™ reagent or ProLong® Gold 
antifade reagent (FRET). Coverslips were visualised 
using either a Olympus Ix71 microscope or Nikon 
Eclipse Ti confocal microscope. Fluorescence intensity 
co-localisation was measured using ImageJ. FRET was 
measured using a multiphoton, time-correlated single-
photon counting (TCSPC) fluorescence lifetime imaging 
microscope (FLIM). FRET efficiency was analysed using 
TRI2 software [70].
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Immunoprecipitation
Experiments were performed 48 hours post-
transfection using GFP Trap® coupled to agarose beads 
(Chromotek) according to the manufacturer’s protocol. 
Briefly, cells were washed 3 times with PBS and lysed 
in lysis buffer (10 mM Tris/Cl pH 7.5; 150 mM NaCl; 
0.5 mM EDTA; 0.5% NP40). GFP Trap® beads were 
equilibrated in dilution/wash buffer (10 mM Tris/Cl pH 
7.5; 150 mM NaCl; 0.5 mM EDTA) before being added 
to the cell lysates. Lysates were then incubated for 1 hour 
at 4°C with constant rolling. The centrifuged beads were 
washed 3 times with dilution/wash buffer and resuspended 
in 6x gel sample buffer.
Invadopodia Assay
Briefly, rhodamine conjugated gelatin was prepared 
as previously described [25]. Ethanol washed coverslips 
were coated with rhodamine conjugated gelatin and 
fixed with gluteraldehyde. The fluorescence was 
quenched with sodium borohydride and washed three 
times with PBS. Cells were seeded on the gelatin coated 
coverslips and incubated for 3 hours at 37°C before being 
immunofluorescently stained. Gelatin degradation of 
each invadopodia producing cell was measured using the 
gelatin degradation plug-in with ImageJ software (a kind 
gift from Laura Machesky, Beatson Institute for Cancer 
Research, Glasgow).
3D Spheroid Invasion Assay
Spheroids were formed by incubating cells at 37°C 
for 3 days in media containing methylcellulose in 96-well 
U-bottomed suspension culture plates. Following this, the 
spheroids were transferred into collagen I matrix. Images 
were taken at day 0 and day 3 or 4 using an Olympus Ix71 
microscope with Image-Pro Plus 7.0 software.
MTT Assay
Cells were plated in a 96 well plate and left to grow 
for 4 days. Cells were stained with methylthiazolyldiphenyl-
tetrazolium bromide (MTT) according to the manufacterers 
instructions and the absorbance at 570nm was measured 
using an Alpha-Fusion plate reader.
Zebrafish Yolk Invasion Assay
All work that was conducted using zebrafish were 
performed under the UK Home Office project licence 
PPL 70/7912 and approved by the King’s College Ethical 
Review committee. 2 dpf embryos were submerged in 
3.5mM MS222, containing penicillin and streptomycin, 
and ~500 A-375M2 cells were injected into the embryo 
yolk sac using a Nikon SMZ-U zoom 1:10 Picospritzer II 
microinjection station. Injected embryos were placed in E3 
media (containing penicillin and streptomycin) and incubated 
at 28°C for 1 hour to recover, then transferred to 35°C for 
the remainder of the experiment. 4 hours post-injection, 
embryos that lacked a clear tumour mass within the yolk sac 
or that had cells outside of the yolk sac were removed and 
humanely killed using 15mM MS222. The percentage of 
embryos with A-375M2 cell tail invasion was calculated 4 
days post-injection. The embryos were then humanely killed 
by the addition of 15mM MS222 for 1 hour.
Statistical analyses
Data sets were compared using two-tailed Students’ 
t-tests and presented as mean ± SEM. Statistical 
significance was accepted for p ≤ 0.05.
ACKNOWLEDGMENTS
The research was funded/supported by the National 
Institute for Health Research (NIHR) Biomedical 
Research Centre based at Guyʼs and St Thomasʼ NHS 
Foundation Trust and Kingʼs College London (NN), 
Breast Cancer Now 2014NovPR356 (ML) and by BBSRC 
grant BB/1022074/1(SAB). The views expressed are those 
of the author(s) and not necessarily those of the NHS, the 
NIHR or the Department of Health.
CONFLICTS OF INTEREST
The authors declare no conflicts of interest.
REFERENCES
1. (2014). Cancer Facts and Figures. American Cancer 
Society).
2. King H, Nicholas NS and Wells CM. Role of p-21-activated 
kinases in cancer progression. International review of cell 
and molecular biology. 2014; 309:347-387.
3. Buccione R, Caldieri G and Ayala I. Invadopodia: 
specialized tumor cell structures for the focal degradation 
of the extracellular matrix. Cancer Metastasis Rev. 2009; 
28:137-149.
4. Stylli SS, Kaye AH and Lock P. Invadopodia: at the cutting 
edge of tumour invasion. Journal of clinical neuroscience : 
official journal of the Neurosurgical Society of Australasia. 
2008; 15:725-737.
5. Yamaguchi H, Wyckoff J and Condeelis J. Cell migration in 
tumors. Curr Opin Cell Biol. 2005; 17:559-564.
6. Gligorijevic B, Wyckoff J, Yamaguchi H, Wang Y, Roussos 
ET and Condeelis J. N-WASP-mediated invadopodium 
formation is involved in intravasation and lung metastasis 
of mammary tumors. J Cell Sci. 2012; 125:724-734.
7. Blouw B, Seals DF, Pass I, Diaz B and Courtneidge SA. A 
role for the podosome/invadopodia scaffold protein Tks5 in 
tumor growth in vivo. Eur J Cell Biol. 2008; 87:555-567.
Oncotarget15www.impactjournals.com/oncotarget
8. Moshfegh Y, Bravo-Cordero JJ, Miskolci V, Condeelis J 
and Hodgson L. A Trio-Rac1-Pak1 signalling axis drives 
invadopodia disassembly. Nat Cell Biol. 2014.
9. Jaffer ZM and Chernoff J. p21-activated kinases: three more 
join the Pak. Int J Biochem Cell Biol. 2002; 34:713-717.
10. Dan C, Kelly A, Bernard O and Minden A. Cytoskeletal 
changes regulated by the PAK4 serine/threonine kinase are 
mediated by LIM kinase 1 and cofilin. J Biol Chem. 2001; 
276:32115-32121.
11. Van Troys M, Huyck L, Leyman S, Dhaese S, 
Vandekerkhove J and Ampe C. Ins and outs of ADF/cofilin 
activity and regulation. Eur J Cell Biol. 2008; 87:649-667.
12. Wells CM, Abo A and Ridley AJ. PAK4 is activated via 
PI3K in HGF-stimulated epithelial cells. J Cell Sci. 2002; 
115:3947-3956.
13. Nayal A, Webb DJ, Brown CM, Schaefer EM, Vicente-
Manzanares M and Horwitz AR. Paxillin phosphorylation 
at Ser273 localizes a GIT1-PIX-PAK complex and regulates 
adhesion and protrusion dynamics. J Cell Biol. 2006; 
173:587-589.
14. Callow MG, Zozulya S, Gishizky ML, Jallal B and Smeal 
T. PAK4 mediates morphological changes through the 
regulation of GEF-H1. J Cell Sci. 2005; 118:1861-1872.
15. Birkenfeld J, Nalbant P, Bohl BP, Pertz O, Hahn KM and 
Bokoch GM. GEF-H1 modulates localized RhoA activation 
during cytokinesis under the control of mitotic kinases. Dev 
Cell. 2007; 12:699-712.
16. Tian X, Tian Y, Gawlak G, Sarich N, Wu T and Birukova 
AA. Control of vascular permeability by atrial natriuretic 
peptide via a GEF-H1-dependent mechanism. J Biol Chem. 
2014; 289:5168-5183.
17. Konold T, Sayers AR, Sach A, Bone GE, van Winden S, 
Wells GA, Simmons MM, Stack MJ, Wear A and Hawkins 
SA. Relationship between clinical signs and postmortem 
test status in cattle experimentally infected with the bovine 
spongiform encephalopathy agent. BMC Vet Res. 2010; 
6:53.
18. Coniglio SJ, Zavarella S and Symons MH. Pak1 and Pak2 
mediate tumor cell invasion through distinct signaling 
mechanisms. Mol Cell Biol. 2008; 28:4162-4172.
19. Barac A, Basile J, Vazquez-Prado J, Gao Y, Zheng Y and 
Gutkind JS. Direct interaction of p21-activated kinase 
4 with PDZ-RhoGEF, a G protein-linked Rho guanine 
exchange factor. J Biol Chem. 2004; 279:6182-6189.
20. Rosenfeldt H, Castellone MD, Randazzo PA and Gutkind 
JS. Rac inhibits thrombin-induced Rho activation: evidence 
of a Pak-dependent GTPase crosstalk. Journal of molecular 
signaling. 2006; 1:8.
21. Semprucci E, Tocci P, Cianfrocca R, Sestito R, Caprara 
V, Veglione M, Castro VD, Spadaro F, Ferrandina G, 
Bagnato A and Rosano L. Endothelin A receptor drives 
invadopodia function and cell motility through the beta-
arrestin/PDZ-RhoGEF pathway in ovarian carcinoma. 
Oncogene. 2015.
22. Qu J, Li X, Novitch BG, Zheng Y, Kohn M, Xie JM, Kozinn 
S, Bronson R, Beg AA and Minden A. PAK4 kinase is 
essential for embryonic viability and for proper neuronal 
development. Mol Cell Biol. 2003; 23:7122-7133.
23. Arias-Romero LE and Chernoff J. A tale of two Paks. Biol 
Cell. 2008; 100:97-108.
24. Ayala I, Baldassarre M, Caldieri G and Buccione R. 
Invadopodia: a guided tour. Eur J Cell Biol. 2006; 
85:159-164.
25. Md Hashim NF, Nicholas NS, Dart AE, Kiriakidis S, 
Paleolog E and Wells CM. Hypoxia-induced invadopodia 
formation: a role for beta-PIX. Open biology. 2013; 
3:120159.
26. Ayala I, Baldassarre M, Giacchetti G, Caldieri G, Tete 
S, Luini A and Buccione R. Multiple regulatory inputs 
converge on cortactin to control invadopodia biogenesis 
and extracellular matrix degradation. J Cell Sci. 2008; 
121:369-378.
27. Wolf K, Wu YI, Liu Y, Geiger J, Tam E, Overall C, Stack 
MS and Friedl P. Multi-step pericellular proteolysis controls 
the transition from individual to collective cancer cell 
invasion. Nat Cell Biol. 2007; 9:893-904.
28. Sabeh F, Shimizu-Hirota R and Weiss SJ. Protease-
dependent versus -independent cancer cell invasion 
programs: three-dimensional amoeboid movement revisited. 
J Cell Biol. 2009; 185:11-19.
29. Wiercinska E, Naber HP, Pardali E, van der Pluijm 
G, van Dam H and ten Dijke P. The TGF-beta/Smad 
pathway induces breast cancer cell invasion through the 
up-regulation of matrix metalloproteinase 2 and 9 in a 
spheroid invasion model system. Breast cancer research and 
treatment. 2011; 128:657-666.
30. Yun CY, You ST, Kim JH, Ho Chung J, Han SB, Shin EY 
and Kim EG. p21-Activated Kinase 4 Critically Regulates 
Melanogenesis via Activation of the CREB/MITF and beta-
Catenin/MITF Pathways. J Invest Dermatol. 2015.
31. Gadea G, Sanz-Moreno V, Self A, Godi A and Marshall 
CJ. DOCK10-mediated Cdc42 activation is necessary for 
amoeboid invasion of melanoma cells. Curr Biol. 2008; 
18:1456-1465.
32. Eguiara A, Holgado O, Beloqui I, Abalde L, Sanchez Y, 
Callol C and Martin AG. Xenografts in zebrafish embryos 
as a rapid functional assay for breast cancer stem-like cell 
identification. Cell Cycle. 2011; 10:3751-3757.
33. Jung DW, Oh ES, Park SH, Chang YT, Kim CH, Choi SY 
and Williams DR. A novel zebrafish human tumor xenograft 
model validated for anti-cancer drug screening. Molecular 
bioSystems. 2012; 8:1930-1939.
34. Teng Y, Xie X, Walker S, White DT, Mumm JS and Cowell 
JK. Evaluating human cancer cell metastasis in zebrafish. 
BMC Cancer. 2013; 13:453.
35. Beaty BT and Condeelis J. Digging a little deeper: The 
stages of invadopodium formation and maturation. Eur J 
Cell Biol. 2014; 93:438-444.
Oncotarget16www.impactjournals.com/oncotarget
36. Friedl P and Wolf K. Tumour-cell invasion and migration: 
diversity and escape mechanisms. Nat Rev Cancer. 2003; 
3:362-374.
37. Fritz RD, Letzelter M, Reimann A, Martin K, Fusco L, 
Ritsma L, Ponsioen B, Fluri E, Schulte-Merker S, van 
Rheenen J and Pertz O. A versatile toolkit to produce 
sensitive FRET biosensors to visualize signaling in time 
and space. Sci Signal. 2013; 6:rs12.
38. Bravo-Cordero JJ, Oser M, Chen X, Eddy R, Hodgson L 
and Condeelis J. A novel spatiotemporal RhoC activation 
pathway locally regulates cofilin activity at invadopodia. 
Curr Biol. 2011; 21:635-644.
39. Berdeaux RL, Diaz B, Kim L and Martin GS. Active Rho 
is localized to podosomes induced by oncogenic Src and is 
required for their assembly and function. J Cell Biol. 2004; 
166:317-323.
40. Zenke FT, Krendel M, DerMardirossian C, King CC, Bohl 
BP and Bokoch GM. p21-activated kinase 1 phosphorylates 
and regulates 14-3-3 binding to GEF-H1, a microtubule-
localized Rho exchange factor. J Biol Chem. 2004; 
279:18392-18400.
41. Driessens MH, Olivo C, Nagata K, Inagaki M and Collard 
JG. B plexins activate Rho through PDZ-RhoGEF. FEBS 
Lett. 2002; 529:168-172.
42. Kasai K, Takahashi M, Osumi N, Sinnarajah S, Takeo T, 
Ikeda H, Kehrl JH, Itoh G and Arnheiter H. The G12 family 
of heterotrimeric G proteins and Rho GTPase mediate Sonic 
hedgehog signalling. Genes Cells. 2004; 9:49-58.
43. Pavey S, Zuidervaart W, van Nieuwpoort F, Packer L, 
Jager M, Gruis N and Hayward N. Increased p21-activated 
kinase-1 expression is associated with invasive potential in 
uveal melanoma. Melanoma Res. 2006; 16:285-296.
44. Zanivan S, Meves A, Behrendt K, Schoof EM, Neilson LJ, 
Cox J, Tang HR, Kalna G, van Ree JH, van Deursen JM, 
Trempus CS, Machesky LM, Linding R, Wickstrom SA, 
Fassler R and Mann M. In vivo SILAC-based proteomics 
reveals phosphoproteome changes during mouse skin 
carcinogenesis. Cell Rep. 2013; 3:552-566.
45. Ong CC, Jubb AM, Jakubiak D, Zhou W, Rudolph J, 
Haverty PM, Kowanetz M, Yan Y, Tremayne J, Lisle 
R, Harris AL, Friedman LS, Belvin M, Middleton MR, 
Blackwood EM, Koeppen H, et al. P21-activated kinase 
1 (PAK1) as a therapeutic target in BRAF wild-type 
melanoma. J Natl Cancer Inst. 2013; 105:606-607.
46. Callow MG, Clairvoyant F, Zhu S, Schryver B, Whyte DB, 
Bischoff JR, Jallal B and Smeal T. Requirement for PAK4 
in the anchorage-independent growth of human cancer cell 
lines. J Biol Chem. 2002; 277:550-558.
47. Radu M, Semenova G, Kosoff R and Chernoff J. PAK 
signalling during the development and progression of 
cancer. Nat Rev Cancer. 2014; 14:13-25.
48. Huynh N, Liu KH, Baldwin GS and He H. P21-activated 
kinase 1 stimulates colon cancer cell growth and migration/
invasion via ERK- and AKT-dependent pathways. Biochim 
Biophys Acta. 2010; 1803:1106-1113.
49. Zhang HJ, Siu MK, Yeung MC, Jiang LL, Mak VC, Ngan 
HY, Wong OG, Zhang HQ and Cheung AN. Overexpressed 
PAK4 promotes proliferation, migration and invasion of 
choriocarcinoma. Carcinogenesis. 2011; 32:765-771.
50. Lu W, Xia YH, Qu JJ, He YY, Li BL, Lu C, Luo X and Wan 
XP. p21-activated kinase 4 regulation of endometrial cancer 
cell migration and invasion involves the ERK1/2 pathway 
mediated MMP-2 secretion. Neoplasma. 2013; 60:493-503.
51. Wells CM and Jones GE. The emerging importance of 
group II PAKs. Biochem J. 2010; 425:465-473.
52. Gringel A, Walz D, Rosenberger G, Minden A, Kutsche 
K, Kopp P and Linder S. PAK4 and alphaPIX determine 
podosome size and number in macrophages through 
localized actin regulation. J Cell Physiol. 2006; 
209:568-579.
53. Murray BW, Guo C, Piraino J, Westwick JK, Zhang C, 
Lamerdin J, Dagostino E, Knighton D, Loi CM, Zager 
M, Kraynov E, Popoff I, Christensen JG, Martinez R, 
Kephart SE, Marakovits J, et al. Small-molecule p21-
activated kinase inhibitor PF-3758309 is a potent inhibitor 
of oncogenic signaling and tumor growth. Proc Natl Acad 
Sci U S A. 2010; 107:9446-9451.
54. Zhang J, Wang J, Guo Q, Wang Y, Zhou Y, Peng H, Cheng 
M, Zhao D and Li F. LCH-7749944, a novel and potent 
p21-activated kinase 4 inhibitor, suppresses proliferation 
and invasion in human gastric cancer cells. Cancer Lett. 
2012; 317:24-32.
55. Viaud J and Peterson JR. An allosteric kinase inhibitor binds 
the p21-activated kinase autoregulatory domain covalently. 
Mol Cancer Ther. 2009; 8:2559-2565.
56. Kesanakurti D, Chetty C, Rajasekhar Maddirela D, 
Gujrati M and Rao JS. Functional cooperativity by direct 
interaction between PAK4 and MMP-2 in the regulation of 
anoikis resistance, migration and invasion in glioma. Cell 
death & disease. 2012; 3:e445.
57. Siu MK, Chan HY, Kong DS, Wong ES, Wong OG, Ngan 
HY, Tam KF, Zhang H, Li Z, Chan QK, Tsao SW, Stromblad 
S and Cheung AN. p21-activated kinase 4 regulates ovarian 
cancer cell proliferation, migration, and invasion and 
contributes to poor prognosis in patients. Proc Natl Acad 
Sci U S A. 2010; 107:18622-18627.
58. Jaiswal M, Gremer L, Dvorsky R, Haeusler LC, Cirstea IC, 
Uhlenbrock K and Ahmadian MR. Mechanistic insights 
into specificity, activity, and regulatory elements of the 
regulator of G-protein signaling (RGS)-containing Rho-
specific guanine nucleotide exchange factors (GEFs) p115, 
PDZ-RhoGEF (PRG), and leukemia-associated RhoGEF 
(LARG). J Biol Chem. 2011; 286:18202-18212.
59. Sakurai-Yageta M, Recchi C, Le Dez G, Sibarita JB, Daviet 
L, Camonis J, D’Souza-Schorey C and Chavrier P. The 
interaction of IQGAP1 with the exocyst complex is required 
Oncotarget17www.impactjournals.com/oncotarget
for tumor cell invasion downstream of Cdc42 and RhoA. J 
Cell Biol. 2008; 181:985-998.
60. Schramp M, Ying O, Kim TY and Martin GS. ERK5 
promotes Src-induced podosome formation by limiting Rho 
activation. J Cell Biol. 2008; 181:1195-1210.
61. Yu CH, Rafiq NB, Krishnasamy A, Hartman KL, Jones GE, 
Bershadsky AD and Sheetz MP. Integrin-matrix clusters 
form podosome-like adhesions in the absence of traction 
forces. Cell reports. 2013; 5:1456-1468.
62. van Helden SF, Oud MM, Joosten B, Peterse N, Figdor CG and 
van Leeuwen FN. PGE2-mediated podosome loss in dendritic 
cells is dependent on actomyosin contraction downstream of 
the RhoA-Rho-kinase axis. J Cell Sci. 2008; 121:1096-1106.
63. Kim JH, Kim HN, Lee KT, Lee JK, Choi SH, Paik SW, 
Rhee JC and Lowe AW. Gene expression profiles in 
gallbladder cancer: the close genetic similarity seen for 
early and advanced gallbladder cancers may explain the 
poor prognosis. Tumour Biol. 2008; 29:41-49.
64. Tsai WC, Chen CL and Chen HC. Protein tyrosine 
phosphatase SHP2 promotes invadopodia formation 
through suppression of Rho signaling. Oncotarget. 2015; 
6:23845-23856.
65. Ispanovic E, Serio D and Haas TL. Cdc42 and RhoA have 
opposing roles in regulating membrane type 1-matrix 
metalloproteinase localization and matrix metalloproteinase-2 
activation. Am J Physiol Cell Physiol. 2008; 295:C600-610.
66. Matsuoka T, Yashiro M, Kato Y, Shinto O, Kashiwagi S and 
Hirakawa K. RhoA/ROCK signaling mediates plasticity of 
scirrhous gastric carcinoma motility. Clin Exp Metastasis. 
2011; 28:627-636.
67. Li YY, Zhou CX and Gao Y. Podoplanin promotes the 
invasion of oral squamous cell carcinoma in coordination 
with MT1-MMP and Rho GTPases. Am J Cancer Res. 
2015; 5:514-529.
68. Yuan XP, Dong M, Li X and Zhou JP. GRP78 promotes the 
invasion of pancreatic cancer cells by FAK and JNK. Mol 
Cell Biochem. 2015; 398:55-62.
69. O’Connor K and Chen M. Dynamic functions of RhoA in 
tumor cell migration and invasion. Small GTPases. 2013; 
4:141-147.
70. Barber PR, Ameer-Beg SM, Gilbey J, Carlin LM, Keppler 
M, Ng TC and Vojnovic B. Multiphoton time-domain 
fluorescence lifetime imaging microscopy: practical 
application to protein-protein interactions using global 
analysis. Journal of the Royal Society Interface. 2009; 
6:S93-S105.
71. Balch CM, Gershenwald JE, Soong SJ, Thompson JF, 
Atkins MB, Byrd DR, Buzaid AC, Cochran AJ, Coit 
DG, Ding S, Eggermont AM, Flaherty KT, Gimotty PA, 
Kirkwood JM, McMasters KM, Mihm MC, Jr., et al. Final 
version of 2009 AJCC melanoma staging and classification. 
J Clin Oncol. 2009; 27:6199-6206.
